AMPHISTA THERAPEUTICS LIMITED
Amphista Therapeutics is a private biotechnology company based in Cambridge that focuses on research and experimental development within the life sciences sector.
Get an alert when AMPHISTA THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£21m
-31.5% vs 2024
Net assets
-£42m
-229.6% lowest in 5 filed years
Employees
53
-5.4% vs 2024
Profit before tax
-£29m
-247% lowest in 5 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Negative shareholders' funds
Net assets
5-year trend · vs Health Care median
Accounts
5-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2020-12-31 | 2021-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|---|---|
| Turnover | £0 | £0 | £10,703,151 | £33,923,239 | £8,795,663 | -74.1% | |
| Operating profit | -£2,412,221 | -£5,989,922 | -£15,139,613 | £12,019,865 | -£14,898,616 | -223.9% | |
| Profit before tax | -£1,826,281 | -£6,920,107 | -£13,050,457 | £19,846,037 | -£29,174,858 | -247% | |
| Net profit | — | — | -£8,969,238 | £19,846,037 | -£29,174,858 | -247% | |
| Cash | £1,450,302 | £21,457,221 | £42,207,352 | £30,667,197 | £21,003,460 | -31.5% | |
| Total assets less current liabilities | £1,058,048 | -£4,652,842 | -£32,438,791 | -£12,599,663 | -£41,529,539 | -229.6% | |
| Net assets | £1,058,048 | -£4,652,842 | -£32,438,791 | -£12,599,663 | -£41,529,539 | -229.6% | |
| Equity | £1,058,048 | — | -£32,438,791 | -£12,599,663 | — | — | |
| Average employees | 12 | 20 | 64 | 56 | 53 | -5.4% | |
| Wages | — | — | £6,335,372 | £6,171,668 | £6,383,736 | +3.4% | |
| Directors' remuneration | — | — | £629,873 | £390,410 | £621,667 | +59.2% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2020-12-31 | 2021-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|
| Operating margin | — | — | -141.5% | 35.4% | -169.4% | |
| Net margin | — | — | -83.8% | 58.5% | — | |
| Return on capital employed | -228.0% | — | — | — | — | |
| Gearing (liabilities / total assets) | — | — | — | 136.0% | 251.2% | |
| Current ratio | — | — | 0.60x | 0.70x | 0.38x | |
| Interest cover | — | -5.68x | -20.31x | 1.83x | -0.99x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Auditor
- PEM Audit Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the Parent Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Group structure
- AMPHISTA THERAPEUTICS LIMITED · parent
- Amphista Therapeutics Inc 100%
Significant events
- “In Q4, 2025 the Company received additional funding of £12.6 million in connection with Series B Tranche 3 based on achieving key milestones with two projects. A restructuring was initiated to right-size the organisation's headcount and wind down non-core R&D activities and to focus relatively more resources on our BRD9 programme.”
- “In March 2026, the Company issued 44,604 £0.0001 Ordinary shares to previous option holders for a total subscription price of £4.64.”
- “In May 2026, the Company secured access to additional financing from existing investors of up to £20m.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
7 active · 7 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BRUMM, Joshua | Director | 2021-09-17 | Dec 1977 | American |
| DZIKOWSKI, Bart | Director | 2023-04-17 | Mar 1976 | Canadian |
| JUNG, Christian Billy, Dr | Director | 2022-12-09 | Sep 1982 | Luxembourger |
| LUZI, Stefan Emanuel | Director | 2021-03-12 | Aug 1983 | Swiss |
| MODIS, Louise Kelly | Director | 2026-03-06 | Jul 1973 | Irish,American |
| ROOSWINKEL, Rogier Wouter, Dr | Director | 2021-03-12 | Aug 1983 | Dutch |
| SCHMIDT, Dominic, Dr | Director | 2022-05-16 | Feb 1982 | British |
Show 7 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CIULLI, Alessio, Dr | Director | 2017-12-20 | 2021-03-12 |
| JINDAL, Satish, Dr | Director | 2020-03-23 | 2021-09-14 |
| MATTESSICH, Antony | Director | 2024-09-02 | 2026-03-06 |
| MUELLERSHAUSEN, Florian, Dr | Director | 2021-03-12 | 2023-04-17 |
| PAREKH, Rajesh Bhikhu, Dr | Director | 2017-12-20 | 2022-05-16 |
| RAJKOMAR, Iyona, Dr | Director | 2017-12-20 | 2019-01-24 |
| THOMPSON, Nicola, Dr | Director | 2019-06-08 | 2023-09-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Advent Life Sciences Llp | Corporate entity | Shares 25–50%, Voting 25–50% | 2019-06-28 | Ceased 2022-12-12 |
| Advent Life Sciences Fund Ii Lp | Corporate entity | Significant influence | 2019-06-28 | Ceased 2019-06-28 |
| Dr Alessio Ciulli | Individual | Shares 25–50% | 2018-02-27 | Ceased 2019-06-28 |
| Advent Life Sciences Llp | Corporate entity | Shares 25–50% | 2017-12-20 | Ceased 2018-02-27 |
| Advent Life Sciences Fund Ii Lp | Corporate entity | Shares 25–50%, Voting 25–50% | 2017-12-20 | Ceased 2017-12-20 |
Filing timeline
Last 20 of 134 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-12-15 MA Memorandum articles
- 2025-12-15 RESOLUTIONS Resolution
- 2025-12-15 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-22 | SH01 | capital | Capital allotment shares | |
| 2026-07-16 | AA | accounts | Accounts with accounts type group | |
| 2026-04-09 | SH01 | capital | Capital allotment shares | |
| 2026-03-10 | AP01 | officers | Appoint person director company with name date | |
| 2026-03-10 | TM01 | officers | Termination director company with name termination date | |
| 2026-01-07 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-01-05 | AA | accounts | Accounts with accounts type group | |
| 2025-12-19 | SH01 | capital | Capital allotment shares | |
| 2025-12-19 | SH01 | capital | Capital allotment shares | |
| 2025-12-15 | MA | incorporation | Memorandum articles | |
| 2025-12-15 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-15 | RESOLUTIONS | resolution | Resolution | |
| 2025-11-28 | SH06 | capital | Capital cancellation shares | |
| 2025-11-28 | SH06 | capital | Capital cancellation shares | |
| 2025-11-28 | SH06 | capital | Capital cancellation shares | |
| 2025-11-28 | SH06 | capital | Capital cancellation shares | |
| 2025-11-28 | SH06 | capital | Capital cancellation shares | |
| 2025-11-28 | SH06 | capital | Capital cancellation shares | |
| 2025-11-28 | SH06 | capital | Capital cancellation shares | |
| 2025-11-28 | SH03 | capital | Capital return purchase own shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 20
- Capital events
- 12
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.